Key Takeaways:
Alignment Healthcare Inc. shares plunged 17% on July 8 after a former executive filed a whistleblower lawsuit alleging accounting manipulation.
"The company misclassified operating expenses as capital costs to artificially inflate adjusted EBITDA," Hakan Kardes, former chief data and transformation officer at Alignment, alleged in the complaint filed in U.S. District Court for the Central District of California.
Kardes, who served at Alignment from 2019 until his resignation in 2025, claimed the practices boosted the company's 2024 and 2025 adjusted EBITDA — a key metric tied to executive compensation and stock performance. He also filed a retaliation complaint with the Occupational Safety and Health Administration in October, seeking damages for lost wages, equity compensation and reputational harm, plus civil penalties under the California Labor Code.
The lawsuit threatens to undermine Alignment's narrative of a dramatic financial turnaround. The company reported 2025 adjusted EBITDA of $109.9 million, up more than 8,000% from a year earlier, on revenue of $3.95 billion — results that helped push the stock to near break-even on a net income basis.
Alignment said it retained an independent accounting firm to review Kardes' allegations, first raised in May 2025, and concluded they were unfounded. "Alignment Healthcare believes these allegations are wholly without merit, intends to defend itself vigorously and is confident it will prevail," a company spokesperson said.
At least two shareholder rights firms have opened investigations. Block & Leviton and Johnson Fistel are probing whether Alignment and certain executives violated federal securities laws. Hagens Berman also launched an investigation following the whistleblower report.
The stock's 17% decline marked its worst single-day drop since February 2024, erasing gains tied to the company's first-quarter 2026 results, which showed sharply higher revenue, a swing to profitability and rising operating cash flow.
The decline puts Alignment shares at their lowest level since the whistleblower allegations first surfaced internally in May 2025. Investors will watch for any restatement of financial results and the outcome of the securities investigations, which could trigger shareholder lawsuits seeking damages.
This article is for informational purposes only and does not constitute investment advice.
